Aspirin News and Research

RSS
Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Study: Medicare 'pay-for-performance' could increase care inequality

Study: Medicare 'pay-for-performance' could increase care inequality

Asbestos induces cell necrosis, promotes tumor growth

Asbestos induces cell necrosis, promotes tumor growth

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck challenges New York jury decision in federal FOSAMAX retrial

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

June issue of Clinic Women's HealthSource provides overview of anemia

June issue of Clinic Women's HealthSource provides overview of anemia

Florida State University College of Medicine to produce set of medical orders for dying patient's care

Florida State University College of Medicine to produce set of medical orders for dying patient's care

Scientists discover septet of overactive genes that control bodily function

Scientists discover septet of overactive genes that control bodily function

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Corgenix receives new European patent for AtherOx technology

Corgenix receives new European patent for AtherOx technology

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Sulindac shuts down cancer cell growth, initiates cell death: Study

Sulindac shuts down cancer cell growth, initiates cell death: Study

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Two variants of LPA gene associated with increased risk of coronary heart disease

Two variants of LPA gene associated with increased risk of coronary heart disease

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Aspirin may not be beneficial for young adults with diabetes

Aspirin may not be beneficial for young adults with diabetes

Women with recurrent miscarriages can have successful pregnancy with supportive care

Women with recurrent miscarriages can have successful pregnancy with supportive care

Study assesses possible links between pain medications and recurrent breast cancer risk

Study assesses possible links between pain medications and recurrent breast cancer risk

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.